ARTICLE | Finance
Money on the table
VCs would have made a bit more if AZ's bid for Omthera had come pre-IPO
June 3, 2013 7:00 AM UTC
Sofinnova Partners and NEA turned a tidy profit from last week's sale of Omthera Pharmaceuticals Inc. (NASDAQ:OMTH) to AstraZeneca plc (LSE:AZN; NYSE:AZN), though it might have been tidier still had the offer come before Omthera's IPO in April.
Omthera's only product candidate is Epanova, an ultra-pure mixture of the free fatty acid forms of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). It is on the verge of an NDA submission to treat severe hypertriglyceridemia...